Overview
Generic Pharmaceutical Companies - Sustainable Competitive Advantages, or lack thereof.
-If yes, describe its components and what the company is doing to maintain/elevate its SCA. Provide specific examples (especially in your area of focus) -If no, describe the issues preventing the company from having an SCA.
Providing specific examples is a key aspect of describing each of the BOR strategies. Also, it is OK to say that those BORs add up to an overall SCA and yet there are some "weaknesses" that you are identifying. Finally, make sure you think about all 3 conditions of an SCA before you determine if they have an SCA (or not).
Below is what the slide showed that I am referring to and the bolded items are what's different compared to the original description.
Based on your prior research, you should be able to answer the question of whether generic pharmaceutical companies has sustainable competitive advantages (Leverage the BOR structure + Innovation radar)
If yes, describe its components and what the company is doing to maintain/elevate its SCA. Provide specific examples (especially in your area of focus)
If no, describe the issues preventing the company from having an SCA
Could identify some gaps even if you have some clearly defined SCA’s (fault lines?)